Biotech company Shanghai Lishan has entered a licensing agreement with computational chemistry company Evogene for a treatment enhancing immunotherapy response. BMC128, a potential first-in-class, microbiome-based therapeutic, is designed to enhance anti-tumour activity. The treatment, developed by Evogene’s subsidiary Biomica, is a live biopharmaceutical consortium composed of four human gut bacterial strains with… Read More
Biomica has revealed encouraging initial findings from an ongoing Phase I clinical trial of its microbiome-based immuno-oncology candidate, BMC128, in combination with an anti-PD1 immune checkpoint inhibitor. The trial is assessing the drug in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell… Read More
Biomica has completed enrolment in its Phase I trial evaluating the safety and tolerability of its microbiome-based immuno-oncology drug, BMC128. Initiated in July 2022, the Phase I trial was designed to evaluate BMC128 in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small… Read More
